MX2021004883A - Metodos y composiciones para tratar apnea del sue?o. - Google Patents

Metodos y composiciones para tratar apnea del sue?o.

Info

Publication number
MX2021004883A
MX2021004883A MX2021004883A MX2021004883A MX2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A MX 2021004883 A MX2021004883 A MX 2021004883A
Authority
MX
Mexico
Prior art keywords
methods
sleep apnea
compositions
treating sleep
hydroxyatomoxetine
Prior art date
Application number
MX2021004883A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence G Miller
Ronald Farkas
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of MX2021004883A publication Critical patent/MX2021004883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021004883A 2018-10-31 2019-07-23 Metodos y composiciones para tratar apnea del sue?o. MX2021004883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
MX2021004883A true MX2021004883A (es) 2021-08-05

Family

ID=67539629

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021004883A MX2021004883A (es) 2018-10-31 2019-07-23 Metodos y composiciones para tratar apnea del sue?o.
MX2024013184A MX2024013184A (es) 2018-10-31 2021-04-28 Metodos y composiciones para tratar apnea del sue?o

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013184A MX2024013184A (es) 2018-10-31 2021-04-28 Metodos y composiciones para tratar apnea del sue?o

Country Status (9)

Country Link
US (3) US20210401790A1 (https=)
EP (1) EP3873454A1 (https=)
JP (2) JP2022506113A (https=)
KR (1) KR20210084481A (https=)
CN (1) CN112930179A (https=)
AU (1) AU2019370091A1 (https=)
CA (1) CA3117766A1 (https=)
MX (2) MX2021004883A (https=)
WO (1) WO2020091862A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
MX2024007764A (es) * 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
US20250049779A1 (en) * 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
CN106714790A (zh) * 2014-07-22 2017-05-24 托马斯·P·杜利 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
MX2024013184A (es) 2024-12-06
JP2022506113A (ja) 2022-01-17
CA3117766A1 (en) 2020-05-07
EP3873454A1 (en) 2021-09-08
US20210401790A1 (en) 2021-12-30
WO2020091862A1 (en) 2020-05-07
JP2024088740A (ja) 2024-07-02
US20250325510A1 (en) 2025-10-23
CN112930179A (zh) 2021-06-08
KR20210084481A (ko) 2021-07-07
US20250114321A1 (en) 2025-04-10
AU2019370091A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2021002321A (es) Nuevos metodos.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500025A1 (en) Cancer treatment combinations
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists
MX2014014813A (es) Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
ZA202002480B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion